Deputy Clinical Director, MGH Cancer Center
Harvard Medical School and Massachusetts General Hospital
Boston, MA, United States
Dr. Kenneth Tanabe serves as a Professor of Surgery at Harvard Medical School, Co-Chief of the Division of Gastrointestinal and Oncologic Surgery and the ESSCO – Slater Family Chair in Surgical Oncology at Massachusetts General Hospital. He also serves as the Deputy Clinical Director of the Massachusetts General Hospital Cancer Center.
Dr. Tanabe maintains a clinical practice in both complex HBP surgery and melanoma surgery. Dr. Tanabe’s translational research laboratory is focused on studies in HPB cancer including development of novel therapies, cancer prevention and modulation of tumor extracellular matrix. He and his laboratory team have genetically engineered Herpes simplex oncolytic viruses to render them highly selective for liver tumors and is conducting a phase I clinical trial in patients with primary and secondary liver cancers. In separate studies, his group identified pathways operant in both liver fibrosis and hepatocellular transformation and is conducting a multi-center clinical trial of EGFR inhibition to manage cirrhosis and prevent hepatocellular carcinoma. His research team has also targeted pathways to modulate pancreatic cancer extracellular matrix and used molecular imaging techniques to assess the modulation, all with an eye towards enhancing therapeutic efficacy of conventional chemotherapy as well as immunotherapies. Dr. Tanabe’s research has been funded by NIH for most of his years on faculty at Harvard Medical School. He has served on multiple NIH study sections and DoD study sections. He has served as PI of a T32 Training Grant in Cancer Biology and has mentored many junior faculty to their first NIH grants. Dr. Tanabe is a specialty board member of the American Board of Surgery (Complex General Surgical Oncology). He serves on several editorial boards and as a Deputy Editor for Annals of Surgical Oncology.
American Cancer Society (Individual(s) Involved: Self): Consultant; Best Doctors (Individual(s) Involved: Self): Consultant; Cancer Experts Now (Individual(s) Involved: Self): Consultant; Innocoll (Individual(s) Involved: Self): Consultant; Leidos (Individual(s) Involved: Self): Consultant; UpToDate (Individual(s) Involved: Self): Royalties
Friday, March 11, 2022
1:35 PM – 1:50 PM CST
Friday, March 11, 2022
2:05 PM – 2:30 PM CST